| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. | 6.2% | -11% | $13,338,337 | -$1,431,000 | 2,796,297 | -9.7% | Anders Hove | 19 Aug 2025 |
As of 30 Sep 2025, 2 institutional investors reported holding 16,393 shares of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB). This represents 0.04% of the company’s total 45,101,565 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 16,393 | $78,346 | -$125,347,286 | $6.66 | 2 |
| 2025 Q2 | 27,903,915 | $125,848,990 | -$3,989,579 | $4.51 | 96 |
| 2025 Q1 | 28,806,277 | $127,612,664 | -$6,925,835 | $4.43 | 102 |
| 2024 Q4 | 28,798,220 | $225,491,854 | -$942,932 | $7.83 | 111 |
| 2024 Q3 | 25,737,929 | $338,544,539 | +$17,304,991 | $13.15 | 105 |
| 2024 Q2 | 24,348,906 | $294,136,627 | +$14,837,664 | $12.08 | 95 |
| 2024 Q1 | 22,993,565 | $373,875,065 | +$49,054,572 | $16.26 | 94 |
| 2023 Q4 | 20,232,989 | $137,987,136 | +$5,157,820 | $6.82 | 93 |
| 2023 Q3 | 19,680,958 | $107,258,625 | +$812,221 | $5.45 | 98 |
| 2023 Q2 | 19,501,430 | $132,412,962 | +$4,779,033 | $6.79 | 94 |
| 2023 Q1 | 19,046,672 | $95,423,185 | -$1,127,392 | $5.01 | 84 |
| 2022 Q4 | 19,342,439 | $94,388,828 | -$55,189,832 | $4.88 | 90 |
| 2022 Q3 | 23,585,540 | $340,103,128 | -$17,897,969 | $14.42 | 95 |
| 2022 Q2 | 24,763,276 | $374,657,143 | -$7,577,417 | $15.13 | 90 |
| 2022 Q1 | 25,303,485 | $300,604,312 | -$14,876,098 | $11.88 | 87 |
| 2021 Q4 | 25,735,284 | $417,099,601 | -$24,204,070 | $16.21 | 94 |
| 2021 Q3 | 26,245,129 | $749,015,343 | -$2,981,846 | $28.54 | 96 |
| 2021 Q2 | 26,145,321 | $886,898,417 | -$1,159,329 | $33.80 | 99 |
| 2021 Q1 | 26,332,523 | $796,209,961 | +$116,007,549 | $30.24 | 116 |
| 2020 Q4 | 22,809,127 | $1,129,308,254 | +$38,442,838 | $49.51 | 115 |
| 2020 Q3 | 21,437,747 | $823,089,252 | +$3,018,102 | $38.39 | 105 |
| 2020 Q2 | 21,284,113 | $919,504,408 | +$53,403,136 | $43.20 | 108 |
| 2020 Q1 | 20,069,737 | $522,452,562 | +$16,002,866 | $26.10 | 80 |
| 2019 Q4 | 19,404,437 | $606,386,157 | +$184,880,658 | $31.25 | 81 |
| 2019 Q3 | 13,139,685 | $342,418,499 | +$56,540,594 | $26.06 | 65 |
| 2019 Q2 | 10,972,436 | $250,918,214 | +$54,344,617 | $22.87 | 59 |
| 2019 Q1 | 8,480,229 | $222,267,926 | -$3,116,524 | $26.21 | 44 |
| 2018 Q4 | 8,686,033 | $175,686,000 | +$16,927,076 | $20.34 | 42 |
| 2018 Q3 | 7,733,371 | $205,387,000 | +$205,387,000 | $26.56 | 38 |